Ameren Corporation announced a net income of $357 million for Q1 2026, translating to diluted earnings per share of $1.28, up from $1.07 in Q1 2025. The increase was driven by earnings from infrastructure investments improving service reliability, despite lower electric sales due to warmer winter weather and higher interest expenses. Ameren reaffirmed its full-year 2026 earnings guidance range of $5.25 to $5.45 per diluted share, assuming normal temperatures for the remainder of the year. The company highlighted ongoing investments across its segments to meet growing energy demand and maintain service quality.
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
The global warehouse shuttle software market is projected to grow from $1.57 billion in 2026 to $2.66 billion by 2030, with a CAGR of 14.1%. Growth is fueled by rising e-commerce, warehouse automation, AI-driven orchestration, and robotic material ha...
The global nucleating and clarifying agents market, valued at $426.33 million in 2025, is projected to grow at a CAGR of 6.8% to reach $868.84 million by 2035. Growth is fueled by rising demand for high-clarity polypropylene packaging, especially in ...
